Significant reduction in myocardial infarctions; will drug be brought back to market?
BERLIN -- The GLP-1 receptor agonist albiglutide (Tanzeum) -- withdrawn from the market in 2017 -- was superior for reducing cardiovascular events in people with type 2 diabetes, researchers reported here.